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Abstract 
Purpose: To examine the time to drug administration in patients with a witnessed cardiac arrest enrolled in the Pre-
Hospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration in Cardiac Arrest 
(PARAMEDIC2) randomised controlled trial.
Methods: The PARAMEDIC2 trial was undertaken across 5 NHS ambulance services in England and Wales with 
randomisation between December 2014 and October 2017. Patients with an out-of-hospital cardiac arrest who were 
unresponsive to initial resuscitation attempts were randomly assigned to 1 mg intravenous adrenaline or matching 
placebo according to treatment packs that were identical apart from treatment number. Participants and study staff 
were masked to treatment allocation.
Results: 8016 patients were enrolled, 4902 sustained a witnessed cardiac arrest of whom 2437 received placebo 
and 2465 received adrenaline. The odds of return of spontaneous circulation decreased in both groups over time 
but at a greater rate in the placebo arm odds ratio (OR) 0.93 (95% CI 0.92–0.95) compared with the adrenaline arm 
OR 0.96 (95% CI 0.95–0.97); interaction OR: 1.03, 95% CI 1.01–1.05, p = 0.005. By contrast, although the rate of survival 
and favourable neurological outcome decreased as time to treatment increased, the rates did not differ between the 
adrenaline and placebo groups.
Conclusion: The rate of return of spontaneous circulation, survival and favourable neurological outcomes decrease 
over time. As time to drug treatment increases, adrenaline increases the chances of return of spontaneous circulation. 
Longer term outcomes were not affected by the time to adrenaline administration. (ISRCTN73485024).
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Introduction
Adrenaline (epinephrine) has been used as a treatment 
for cardiac arrest for over 50  years [1]. Observational 
studies found that adrenaline was effective at achieving 
a return of spontaneous circulation (ROSC) and short 
term survival, but there was uncertainty about its effects 
on long-term survival and survival with a favourable neu-
rological outcome [2]. The PARAMEDIC2 study was a 
large randomised, double blind, placebo controlled trial 
which evaluated the effect of standard dose adrenaline 
(1 mg every 3–5 min) in adults with out of hospital car-
diac arrest (OHCA) [3]. The trial found that adrenaline 
increased ROSC and survival to 30  days/hospital dis-
charge but did not find evidence of improved survival 
with a favourable neurological outcome at hospital 
discharge.
Early descriptions of the use of adrenaline as an adjunct 
to assist with resuscitation from cardiopulmonary arrest 
emphasised the importance of early administration [4, 
5]. One possible explanation for the failure of adrenaline 
to improve neurological outcomes may be if treatment 
is administered too late after the onset of cardiac arrest. 
This hypothesis is supported by animal studies [6–8] 
and observational studies of cardiac arrest both in- and 
out-of-hospital [9, 10], which suggest better outcomes 
the earlier that adrenaline is administered. However, the 
findings of observational studies need to be interpreted 
with caution because of likely confounding. Resuscitation 
time bias occurs when interventions are given during the 
treatment of cardiac arrest (e.g. tracheal intubation, drug 
administration) [11]. As outcomes are worse the longer 
the duration of a cardiac arrest, late administration of the 
intervention is biased by the fact that the duration of car-
diac arrest has been longer.
The influence of resuscitation time bias may be reduced 
by the analysis of time to intervention from double blind, 
randomised controlled trials, where we would expect no 
difference in the timing of drug administration between 
adrenaline and placebo groups. The aim of this paper is 
to examine the effect of time to drug administration in 
the PARAMEDIC2 study on ROSC, survival to discharge 
and neurological outcome [3].
Methods
Study design
The background to the trial, methods and baseline char-
acteristics of the randomised patients have been previ-
ously reported [3, 12].
The protocol was approved South Central–Oxford 
C Research Ethics Committee and the Medicines 
and Healthcare Products Regulatory Authority. Trial 
oversight was provided by independent trial steering and 
data monitoring committees. The trial was designed and 
conducted in accordance with the principles of Good 
Clinical Practice, the Directive 2001/20/EC of the Euro-
pean Parliament and Council, which was transposed 
into legislation in the United Kingdom by the Medicines 
for Human Use (Clinical Trials) Regulations. Due to 
the emergency nature of the trial, it was not possible to 
obtain consent before enrolment. In accordance with the 
clinical trial regulations, and with permission from the 
ethics committee, consent to continue was sought after 
the initial emergency had passed.
In brief, PARAMEDIC-2 was a multicentre double-
blinded placebo-controlled trial conducted by five 
National Health Service ambulance services in the 
United Kingdom from December 2014 to October 2017. 
Adult patients treated for OHCA who were not success-
fully resuscitated by means of defibrillation or CPR, and 
who met predetermined eligibility criteria, were ran-
domly allocated to receive parenteral adrenaline or saline 
placebo. Randomisation occurred when trial paramedics 
opened packs containing prefilled 10 ml syringes loaded 
with either ten 1 mg doses of adrenaline or ten doses of 
0.9% saline. Trial packs and their contents were identical 
in appearance and carried a unique identification num-
ber. In all other respects identical paramedic resuscita-
tion protocols were followed [13].
Randomisation of drug packs to ambulance services 
was achieved using the minimisation method with an 
allocation ratio of 1:1. Patients, paramedics and trial staff 
were blinded to treatment allocation. The time of drug 
administration was entered manually in the ambulance 
clinical record.
Patients and the public were involved during the con-
ception, design, conduct, interpretation and dissemi-
nation stages of the trial. Involvement was integrated 
through patient and public membership of the core 
research team and Trial Steering Committee, public con-
sultation meetings and regular meetings with a patient 
and public advisory group.
Statistical analysis
Examining the influence of time to treatment was an a 
priori, planned analysis of the PARAMEDIC2 trial.
Take‑home message 
Rates of survival and favourable neurological outcome decrease 
the longer a patient is in cardiac arrest. Thus, the duration of cardiac 
arrest, rather than time to drug administration, is the key determi-
nant of outcome.
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The time interval to administration of treatment was 
recorded from the time the first 999 emergency call was 
received to administration of the trial drug. Analyses 
assessed the primary outcome: survival at 30  days, and 
secondary outcomes: survival at discharge, ROSC at hos-
pital admission and neurological outcome at discharge 
from hospital. The neurological outcome was measured 
using a modified Rankin scale (mRS) assessment [ranging 
from 0 (no symptoms) to 6 (death)] where a score of 0–3 
inclusive was considered favourable [14].
The effect of time to administration of trial drug on 
primary and secondary outcomes was examined within 
the group of patients whose cardiac arrest was EMS or 
bystander witnessed. Analysis was restricted to these 
patients because the delay between cardiac arrest and 
the 999 call was unknown for unwitnessed cases. Some 
of the witnessed patients (n = 42) were found to have a 
treatment time interval in excess of 60  min. Sensitivity 
analyses were performed to assess the influence of these 
extreme outliers.
All statistical analyses were undertaken using Stata, 
version 15.1 SE.
Baseline characteristics were summarised using mean, 
(standard deviation) or median and inter-quartile range 
for continuous data and number of patients (with per-
centages) for categorical data.
Logistic regression models were fitted for each of the 
four outcomes. For the unadjusted analyses, continu-
ous time to administration of trial drug and the allo-
cated treatment were modelled as explanatory factors. 
An interaction of these variables was fitted to model the 
effect of time on the estimated treatment effects. The 
adjusted analyses were corrected for pre-specified covari-
ates [12] which included age, gender, aetiology (medi-
cal, traumatic, drowning, drug overdose, electrocution, 
asphyxial), initial rhythm (VF, pulseless VT, AED shock-
able, asystole, PEA/EMD, bradycardia, AED non-shock-
able), witness type (EMS, bystander) and bystander CPR 
(yes, no). For the adjusted models, initially, multivari-
able fractional polynomial models were fitted to deter-
mine best fit of model, as there was no reason to assume 
a constant proportional change in the odds ratio over 
time. Three transformations of the time variable were 
assessed: linear, first and second degree power transfor-
mations (e.g. time,  timea and  timea + timeb, respectively, 
where a and b are powers). Model fits were compared 
using Akaike information criterion (AIC). The smallest 
AIC indicated the best fit model. In the case of the lin-
ear model being the best fit model, the treatment effects 
over time were further assessed using logistic regression. 
The risk difference represents the difference averaged 
over time in the incidence of the outcome between the 
two interventions (having adjusted out the effect of the 
important covariates).
In a post-hoc analysis, the models were replicated sepa-
rately for shockable and non-shockable sub-groups.
Role of the funding source
The trial was funded by the Heath Technology Assess-
ment (HTA) Programme of the National Institute for 
Health Research (NIHR) (12/127/126). The funders had 
no role in the trial design, data collection or analysis, or 
in the writing of this report. The Warwick Clinical Tri-
als Unit undertook data management activities. The trial 
statisticians assume responsibility for the integrity of the 
data and its analysis. The Current Controlled Trials num-
ber is ISRCTN73485024.
Results
Of 8014 patients enrolled in the study (3999 to placebo 
and 4015 to adrenaline), removal of unwitnessed cases 
and where the status of witness was unknown, reduced 
the numbers to 2437 (60.9%) and 2465 (61.4%), respec-
tively. A further 50 patients with missing treatment time 
(23 from placebo and 27 from the adrenaline arm) were 
excluded. A CONSORT diagram demonstrates the rates 
of follow-up according to outcome (Fig. 1).
Baseline characteristics were summarised for the wit-
nessed patients with treatment delay ≤ 60  min and are 
shown in Table  1. The interval between 999 emergency 
call and treatment administration were similarly distrib-
uted in both groups (Fig. 2).
The results of the multivariable fractional polynomial 
indicated that the linear fit was the most appropriate to 
the data for all outcomes.
Return of spontaneous circulation
Using the logistic regression model, it was estimated that 
when the trial drug was administered immediately after 
cardiac arrest (i.e. at time = 0) the odds of ROSC for those 
receiving adrenaline was more than twice that of patients 
given placebo (OR: 2.11, 95% CI 1.40–3.18, p < 0.001.) 
The risk difference (RD) between treatment arms was 
estimated at 0.177 (95% CI 0.155–0.198, p < 0.001).
The odds of ROSC (as opposed to no ROSC) at hos-
pital admission decreased at a greater rate in the pla-
cebo arm compared with the adrenaline arm—in the 
placebo group by 0.93 (95% CI 0.92–0.95, p < 0.001) for 
every unit increase in time (min) and by 0.96 (95% CI 
0.95–0.97, p < 0.001) in the adrenaline group. As timing 
of drug administration increases, the odds ratio of ROSC 
increases between the adrenaline and placebo groups by 
a factor of 1.03 for every additional minute (OR: 1.03, 
95% CI 1.01–1.05, p = 0.005).
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Figure  3 displays these results as probability of ROSC 
over time. For those given adrenaline immediately after 
cardiac arrest the probability of ROSC is 0.46 (95% CI 
0.40–0.52) compared to 0.30 (95% CI 0.23–0.37) for 
those given placebo. After a delay in treatment of 40 min 
the probability reduces to 0.16 (95% CI 0.13–0.19) and 
0.03 (95% CI 0.02–0.04), respectively.
Randomised
(pack opened)
(n=8,103)
Allocated to Placebo
Received allocated intervenon (n=3,999)
Allocated to Adrenaline
Received allocated intervenon (n=4,015)
Enrolled in the study
(pack opened, drug given)
(n=8,016)
Post-randomisaon exclusions (n=87)
• DNAR in place (n=4)
• Asthma (n=6)
• ROSC before drug given (n=22)
• Pregnant (n=2)
• Syringes broken or contaminated
(n=4)
• Unable to obtain IV access (n=2)
• Unknown (n=47)
Witnessed with recorded treatment me
(n=2,414)
Lost to follow-up:
LTFU of ROSC at hospital admission (n=11)
LTFU of survival at 30 days (n=3)
LTFU of survival at hospital discharge (n=3)
LTFU of favourable neurological outcome at
discharge (n=4)
Witnessed with recorded treatment me
(n=2,438)
Lost to follow-up:
LTFU of ROSC at hospital admission (n=24)
LTFU of survival at 30 days (n=3)
LTFU of survival at hospital discharge (n=6)
LTFU of favourable neurological outcome at
discharge (n=8)
Excluded:
Treatment delay >60 minutes (n=21)
Analysed:
ROSC outcome at hospital admission (n=2,382)
Survival outcome at 30 days (n=2,390)
Survival outcome at hospital discharge (n=2,390)
Favourable neurological outcome at discharge
(n=2,389)
Excluded:
Treatment delay >60 minutes (n=21)
Analysed:
ROSC outcome at hospital admission (n=2,393)
Survival outcome at 30 days (n=2,414)
Survival outcome at hospital discharge (n=2,411)
Favourable neurological outcome at discharge
(n=2,409)
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Missing allocaon
• Reason 1: lost pack number (n=2)
Not witnessed (n=1,505)
Unknown (n=57)
Not witnessed (n=1,498)
Unknown (n=52)
Missing treatment me (n=23) Missing treatment me (n=27)
Witnessed cases (n=2,437) Witnessed cases (n=2,465)
Fig. 1 CONSORT flow diagram
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Survival to 30 days and hospital discharge
The rate of survival to 30 days decreased as time to treat-
ment increased in both the placebo and adrenaline group 
(odds: 0.92, 95% CI 0.89–0.95, p < 0.001 and 0.9, 0.88–
0.93, p < 0.001, respectively).
The continuous covariate logistic model, suggests that 
the odds ratio of surviving to 30  days in the adrenaline 
arm (as opposed to placebo) did not change relative to 
placebo in relation to the time of drug administration 
(p = 0.41. risk difference: 0.009, 95% CI − 0.002 to 0.019, 
p = 0.103). The curves appear to converge after approxi-
mately 30 min from the time of cardiac arrest. However, 
these results include few cases at the two extremes of the 
time band and, therefore, have to be interpreted with 
caution. A similar pattern of results was noted for sur-
vival to hospital discharge (risk difference: 0.008, 95% CI 
− 0.002 to 0.019, p = 0.122).
Table 1 Patient characteristics by treatment arm for witnessed cases only (n = 4810)
a n = 3 patients had no recorded age
b Includes EMS witnessed cases
Placebo (n = 2393) Adrenaline (n = 2417) Overall (n = 4810)
Age (years)
Mean (SD) 70.94 (15.26) 71.07 (15.3) 71a (15.28)
Median (IQR) 73.57 (21.10) 73.48 (21.45) 73.5a (21.28)
Time to treatment (min)
Mean (SD) 21.73 (9.73) 21.72 (9.48) 21.73 (9.6)
Median (IQR) 20.93 (11.83) 21.08 (11.64) 21.00 (11.75)
Gender
Male 1548 (64.69%) 1556 (64.38%) 3104 (64.53%)
Female 845 (35.31%) 861 (35.62%) 1706 (35.47%)
Initial rhythm
Shockable 595 (24.86%) 604 (24.99%) 1199 (24.93%)
Of which:
 VF 542 (91.09%) 563 (93.21%) 1105 (92.16%)
 Pulseless VT 19 (3.19%) 20 (3.31%) 39 (3.25%)
 AED shockable 34 (5.71%) 21 (3.48%) 55 (4.59%)
 Non-shockable 1765 (73.76%) 1763 (72.94%) 3528 (73.35%)
Of which:
 Asystole 1045 (59.21%) 1,000 (56.72%) 2045 (57.96%)
 PEA/EMD 686 (38.87%) 724 (41.07%) 1410 (39.97%)
 Bradycardia 14 (0.79%) 20 (1.13%) 34 (0.96%)
 AED non-shockable 20 (1.13%) 19 (1.08%) 39 (1.11%)
Unknown 33 (1.38%) 50 (2.07%) 83 (1.73%)
Aetiology
Medical (presumed cardiac) 2273 (94.99%) 2297 (95.04%) 4570 (95.01%)
Traumatic cause 36 (1.5%) 40 (1.65%) 76 (1.58%)
Drowning 0 (0%) 3 (0.12%) 3 (0.06%)
Drug overdose 24 (1%) 22 (0.91%) 46 (0.96%)
Electrocution 1 (0.04%) 0 (0%) 1 (0.02%)
Asphyxial 32 (1.34%) 28 (1.16%) 60 (1.25%)
Unknown 27 (1.13%) 27 (1.12%) 54 (1.12%)
Witnessed by
EMS witnessed 452 (18.89%) 438 (18.12%) 890 (18.5%)
Bystander witnessed 1941 (81.11%) 1979 (81.88%) 3920 (81.5%)
Bystander CPR
Yes 1353 (56.54%) 1386 (57.34%) 2739 (56.94%)
Nob 1012 (42.29%) 1000 (41.37%) 2012 (41.83%)
Unknown 28 (1.17%) 31 (1.28%) 59 (1.23%)
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The probability of survival had the trial drug been 
administered immediately after cardiac arrest is esti-
mated to be 0.17 (95% CI 0.11–0.23) in the adrenaline 
group and 0.12 (95% CI 0.07–0.18) in the placebo group. 
When time from 999 call to treatment is 40  min the 
estimated probability of survival in both groups drops 
to < 0.01 (see Fig. 3).
Favourable neurological outcome at discharge
The proportion of patients who survived to hospital dis-
charge with a favourable neurological outcome decreased 
with time in both the adrenaline and the placebo group 
(p < 0.001).
The odds ratio for favourable neurological outcome in 
the logistic model did not change over time (p = 0.39. risk 
difference: 0.004, 95% CI − 0.006 to 0.013, p = 0.450). The 
curves appear to converge after approximately 20  min 
from the time of cardiac arrest. This is limited by very 
low frequency counts and, therefore, should be inter-
preted with caution.
Figure  3 shows that the probability of survival with 
favourable neurological outcome is estimated to be 0.16 
(adrenaline, 95% CI 0.09–0.22) and 0.12 (placebo, 95% 
CI 0.06–0.17) when time to treatment is zero minutes 
and < 0.01 for both groups when time to treatment is 
40 min.
Initial rhythm
Results of separate analyses of patients with shockable 
and non-shockable rhythms (see electronic supplemen-
tal material) were very similar to the overall witnessed 
group, with the exception of patients with an initial 
shockable rhythm for ROSC at hospital admission, where 
the curves for difference in rate of ROSC overlapped dur-
ing the first ten minutes of cardiac arrest (Fig. 4). The risk 
difference for those with shockable rhythms was 0.131 
(95% CI 0.080–0.182, p < 0.001) and for non-shockable 
rhythms the risk difference was 0.192 (95% CI 0.169–
0.215, p < 0.001). However, these results have to be inter-
preted with caution, due to the small number of patients 
within some of the time categories.
Sensitivity analyses and model selection
Sensitivity analysis showed that the removal of 42 
patients with time to treatment in excess of 60  min (21 
each arm) did not impact upon the conclusions of the 
analysis, therefore, the data were truncated at 60 min to 
maintain clinical plausibility and all results presented are 
based on these data.
Comparison of models with linear and non-linear time 
covariates identified that linear models offered the best 
fit for all four outcome variables. The results of model 
selection can be found in the electronic supplementary 
material.
Fig. 2 Distribution of time to treatment by treatment type
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Unadjusted analyses yielded similar results to the 
reported adjusted analyses (electronic supplementary 
material).
Discussion
The main findings of this study are that the rates of ROSC 
on arrival at hospital, survival and favourable neurologi-
cal outcome all decreased as the interval from cardiac 
arrest to the administration of drug or placebo increased. 
The best outcomes are seen early after the onset of car-
diac arrest. Models of time to drug administration 
showed a pattern which suggests that the relative effects 
of adrenaline to placebo on ROSC increased over time, 
although the absolute difference remained fairly consist-
ent over time. By contrast, the effects of adrenaline rela-
tive to placebo on survival and favourable neurological 
outcomes did not change over time.
The observation that ROSC, survival and neurological 
outcomes deteriorate the longer a patient is in cardiac 
arrest is consistent with previous studies [15–18]. This 
underlies the phenomenon known as resuscitation time 
bias, whereby interventions given early after the onset 
of cardiac arrest appear to be beneficial relative to late 
interventions, but the better outcomes are in fact related 
to earlier treatment [11, 19]. The randomised design of 
the PARAMEDIC2 study removes the influence of resus-
citation time bias, allowing an unbiased assessment of 
changes in treatment effect over time. The study reaf-
firms that during cardiac arrest, any traditional time-to 
intervention analyses are likely to be severely biased. It 
highlights the importance of more sophisticated statisti-
cal analyses of observational data which can partly deal 
with this problem [11, 20].
The novel finding that the effects of adrenaline on 
ROSC compared with placebo increase over time are 
consistent with experimental studies. In a rat model 
of cardiac arrest Angelos et  al. found no difference 
between placebo and adrenaline in the rate of ROSC 
in cardiac arrests of very short duration (less than 
2 min) [21]. As the duration of cardiac arrest increased, 
Fig. 3 a Adjusted probability (95% CI) of ROSC over time by treatment arm. Model adjusted for age, gender, rhythm, aetiology, witness type and 
bystander CPR. Treatment OR (t = 0): 2.11, 95% CI 1.40–3.18, p < 0.001. Interaction OR: 1.03, 95% CI 1.01–1.05, p = 0.005. b Adjusted probability (95% 
CI) of survival to 30 days over time by treatment arm. Model adjusted for age, gender, rhythm, aetiology, witness type and bystander CPR. Treatment 
OR (t = 0): 1.78, 95% CI 0.79–4.00, p = 0.16. Interaction OR: 0.98, 95% CI 0.94–1.03, p = 0.41. c Adjusted probability (95% CI) of survival to hospital dis-
charge over time by treatment arm. Model adjusted for age, gender, rhythm, aetiology, witness type and bystander CPR. Treatment OR (t = 0): 1.46, 
95% CI 0.654–3.30, p = 0.36. Interaction OR: 0.99, 95% CI 0.95–1.04, p = 0.75. d Adjusted probability (95% CI) of favourable neurological outcome at 
discharge over time by treatment arm. Model adjusted for age, gender, rhythm, aetiology, witness type and bystander CPR. Treatment OR (t = 0): 
1.65, 95% CI 0.66–4.11, p = 0.28. Interaction OR: 0.98, 95% CI 0.93–1.03, p = 0.39
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adrenaline played an increasingly important role in 
restoring ROSC. These findings are consistent with the 
3-phase cardiac arrest model described by Weisfeldt 
and Becker which reflects the time sensitive changes 
in metabolic and physiological profiles the longer the 
duration of a cardiac arrest. In this model, vasopres-
sors are recommended during the later circulatory and 
metabolic phases (> 4 min) [22]. At a cellular level this 
can be explained as within minutes of the onset of car-
diac arrest, myocardial adenosine triphosphate levels 
Fig. 4 a Adjusted probability (95% CI) of ROSC over time by treatment arm (shockable rhythms only). Model adjusted for age, gender, rhythm, 
aetiology, witness type and bystander CPR. Treatment OR (t = 0): 1.10, 95% CI 0.52–2.32, p = 0.81. Interaction OR: 1.03, 95% CI 0.99–1.07, p = 0.10. b 
Adjusted probability (95% CI) of ROSC over time by treatment arm (non-shockable rhythms only). Model adjusted for age, gender, rhythm, aetiol-
ogy, witness type and bystander CPR. Treatment OR (t = 0): 3.22, 95% CI 1.90–5.47, p < 0.001. Interaction OR: 1.03, 95% CI 1.00–1.06, p = 0.03
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decrease, leading to the disruption of normal myocar-
dial cellular homeostasis [6]. Unlike the heart, the brain 
is more sensitive to tissue ischaemia as it has no myo-
globin oxygen stores [23, 24]. Furthermore, CPR and 
vasopressors may be less effective at restoring mito-
chondrial function in the brain than it is at restoring 
cardiac mitochondrial performance [25].
A key unanswered question in PARAMEDIC2 was the 
influence of time to drug administration. The time from 
collapse to drug treatment was on average 22 min. This 
is longer than the interval during in-hospital cardiac 
arrest (average 3  min) [9, 10] and during the majority 
of animal cardiac arrest models (average 9.5 min) [26]. 
The timing is similar to a systematic review of time to 
drug administration across 17 studies [19.4  min (95% 
CI 12.8–25.9)] [27] and with more recent studies (range 
13–24 min) [28–31]. This analysis of time to treatment 
shows that the shorter the time to treatment, whether 
treatment was adrenaline or placebo, is associated with 
the best outcomes. Current treatment algorithms rec-
ommend that CPR is started (and if indicated defibrilla-
tion) before adrenaline is administered. This finding is, 
therefore, probably related to a shorter duration of low 
or no flow time after the onset of cardiac arrest. The 
later administration of adrenaline increases the chances 
of ROSC relative to placebo but without incremental 
improvement in longer term outcomes. This discord-
ance may in part explain improved ROSC, but smaller 
effects on long-term survival and minimal influence on 
favourable neurological outcome.
The present study explored if the treatment effects 
differed according to whether the initial rhythm was 
shockable or non-shockable. In an analysis of in-hos-
pital cardiac arrests with an initial shockable rhythm, 
Andersen et  al. found that very early (within 2  min of 
first defibrillation) compared with no or late adrena-
line (> 2 min) was associated with lower rates of ROSC 
(OR 0.71, 95% CI 0.60–0.83), survival (OR 0.70, 95% CI 
0.59–0.82) and survival with a favourable neurological 
outcome (OR 0.69, 95% CI 0.58–0.83) [9]. In OHCA 
(time to drug administration 13 min), Ewy et al. found 
that delayed adrenaline reduced survival (aOR 0.94, 
95% CI 0.91–0.97) in patients with shockable rhythms 
but did not affect neurological outcomes. Hayashi 
noted both improved survival and better neurologi-
cal outcomes in those who received adrenaline within 
10  min of cardiac arrest [32]. The present study sug-
gests that very early adrenaline does not increase the 
rates of ROSC in patients with an initially shockable 
rhythm.
Overall outcomes are worse where the initial rhythm 
is non-shockable. During in-hospital cardiac arrest, 
Donnino et  al. noted a stepwise reduction in survival 
and favourable neurological outcome with delays in 
adrenaline administration exceeding 1–3  min [10]. In 
OHCA, Hansen et  al. found that every minute delay to 
the administration of adrenaline decreased survival (OR 
0.96, 95% CI 0.95–0.98) and favourable neurological out-
comes (OR 0.94, 95% CI 0.89–0.98) [33]. By contrast, the 
present study was consistent with Ewy et  al. in finding 
no difference in longer term outcomes according to the 
time of adrenaline administration for patients with non-
shockable rhythms [29].
Compared with observational studies, the randomised 
double-blind design of this trial reduced the influence of 
confounding (due to patient characteristics and resuscita-
tion time bias), performance and ascertainment bias. The 
pragmatic nature of the trial, embedded within National 
Health Service Ambulance Services, increased generalis-
ability to similar settings. Although defined a priori, anal-
ysis of time to drug administration was not the primary 
intent of the PARAMEDIC2 study. As such, the results 
should be considered exploratory and interpreted with 
caution. The study pooled EMS-witnessed and bystander 
witnessed cardiac arrests as there were insufficient num-
bers to analyse separately. For the sub-group analysis 
according to rhythm, patients were analysed in groups 
according to their initial presenting rhythm. This does 
not account for any subsequent rhythm transitions. The 
relatively few patients with an initial shockable mean the 
findings need to be interpreted cautiously. Post-resus-
citation care treatments (targeted temperature man-
agement, haemodynamic and ventilator management, 
percutaneous coronary intervention, prognostication) 
were recommended but were not strictly protocolised 
or monitored. It is possible that different approaches to 
post-resuscitation care may have influenced longer term 
outcomes. Alternative dosing regimens such as higher 
or lower doses, use of a continuous infusion, may have 
produced different results. Finally, the findings of worse 
outcomes overall with later interventions should be con-
sidered when designing and estimating sample sizes in 
future trials.
In conclusion, rate of ROSC, survival and favourable 
neurological outcomes reduce the longer the duration 
of cardiac arrest. This confirms that early treatment of 
cardiac arrest rather than specifically the administra-
tion of adrenaline, provides the best outcomes. As time 
progresses, the effects of adrenaline on the rate of ROSC 
increase relative to placebo. By contrast, the rate of sur-
vival and favourable neurological outcomes was not sub-
stantively different over time between the adrenaline and 
placebo groups.
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